KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Esperion Therapeutics (ESPR) Accumulated Depreciation & Amortization (2018 - 2025)

Esperion Therapeutics' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 5.06% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, up 5.06%, while the annual FY2025 figure was $2.2 million, 5.06% up from the prior year.
  • Accumulated Depreciation & Amortization reached $2.2 million in Q4 2025 per ESPR's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.6 million in Q4 2022 to a low of $2.0 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.2 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 30.55% in 2021, then decreased 21.13% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.1 million in 2021, then rose by 24.38% to $2.6 million in 2022, then fell by 21.13% to $2.0 million in 2023, then rose by 3.08% to $2.1 million in 2024, then rose by 5.06% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Accumulated Depreciation & Amortization are $2.2 million (Q4 2025), $2.1 million (Q4 2024), and $2.0 million (Q4 2023).